Profit Warning, Approval, Settlement, Expansion

MarcusWelcome to the Access Brief — your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, and it's great to have you with us today.

SaraAnd I'm Sara. Always good to be here — and I'll say, the profit warning from HCA this morning has me thinking about system vulnerabilities.

MarcusSame here. We're looking at HCA's profit warning and what it signals for US healthcare access. Then the SubQ Leqembi approval and its HEOR implications. The FTC settlement with CVS Caremark over insulin pricing. And ICER's expansion of scientific advice services.

SaraThat second one on SubQ Leqembi is particularly interesting — the evidence generation for accelerated approvals is becoming a critical access lever.

MarcusExactly. Let's get into it.

MarcusHCA issued a profit warning this week, citing lower patient volumes and higher costs. This isn't just a financial story; it's a signal about the sustainability of hospital systems, especially in the US. We're seeing pressure on margins that could cascade to access.

SaraThat's one read — but what strikes me is the patient impact. If HCA is pulling back on services, we're likely to see reduced access in certain regions, particularly for lower-margin services. The budget impact for payers could be significant if they have to cover more referrals to other systems.

MarcusAnd that connects to something I keep coming back to: the consolidation in healthcare. When major systems like HCA face headwinds, it's not just about their stock price. It's about the entire ecosystem of care and how that affects the evidence we generate for new therapies.

SaraThe part that gives me pause is the timing. This isn't post-pandemic fatigue; it's a structural shift. I wonder if that's the full picture though — are we seeing a real reduction in patient demand or just a shift in where care is delivered? The data isn't clear yet.

MarcusFair point. But the market reaction was immediate, suggesting investors see this as a trend. For HEOR, this means we might need to adjust our models to account for system-level financial stress. If hospitals are cutting costs, how does that affect the adoption curve for new technologies?

SaraThat's a critical question. It also raises the issue of opportunity cost — if a health system is under financial pressure, they may prioritize treatments with clear immediate cost savings over those with longer-term value. That could create a bifurcation in access.

MarcusExactly. And that's something we'll be watching closely.

SaraThe FDA approval of SubQ Leqembi is significant, but the route matters. It's an accelerated approval based on surrogate endpoints. This creates an immediate HEOR challenge: generating real-world evidence to confirm clinical benefit.

MarcusThat's a fair read. But let's not undersell the innovation here. A subcutaneous formulation for Alzheimer's is a game-changer for patient convenience. That alone could shift the value proposition. The HEOR community will need to track both the clinical outcomes and the patient-reported outcomes on tolerability and adherence.

SaraI'd push back slightly on that. The evidence bar for accelerated approvals is high, and the FDA requires post-marketing studies. The real question is whether the RWE will confirm the benefit. If it doesn't, we could see coverage restrictions. The budget impact for payers could be substantial given the price and the population.

MarcusThat's a valid concern. But what's interesting is the timing: the approval comes as CMS is also evaluating coverage. The HEOR strategy here must be dual: supporting the accelerated approval with early RWE while also engaging with HTA bodies on the full value proposition. The convenience angle is a real differentiator.

SaraConvenience is important, but we can't ignore the cost. The price point for these therapies is enormous. And if the RWE doesn't confirm the benefit, payers will be quick to restrict access. The risk of a coverage gap is real.

MarcusI agree that the risk is there, but the innovation here is undeniable. The HEOR community must be proactive in generating the evidence needed to bridge that gap. It's a test case for how we handle accelerated approvals in the Alzheimer's space.

MarcusThe FTC settlement with CVS Caremark over insulin pricing is a landmark moment. It addresses the practice of spread pricing, where PBMs charge more for insulin than they reimburse pharmacies. This could have ripple effects across the PBM industry.

SaraThat's one read — but what I'm focused on is the patient impact. This settlement aims to reduce out-of-pocket costs for insulin. However, the devil is in the details. How will the savings be passed through? And what does this mean for the broader insulin market? We could see more consolidation among manufacturers.

MarcusAnd that connects to the HEOR evidence we need. If insulin prices are compressed, how does that affect the value proposition for new insulins or biosimilars? The cost-effectiveness thresholds might shift. Also, the settlement could change the way we model budget impact for diabetes therapies.

SaraThe part that gives me pause is the precedent. This is the first major federal action against spread pricing. If it works, we might see more scrutiny on PBMs. But will it actually lower costs for patients? Or will the savings be absorbed elsewhere? The evidence so far is mixed.

MarcusFair point. But the fact that the FTC is taking action signals a shift in the regulatory landscape. For HEOR, this means we need to anticipate how PBM practices might evolve and adjust our evidence strategies accordingly. The focus on transparency is a win for the field.

SaraTransparency is good, but I'm not convinced this will solve the broader access issues. Insulin is just one piece. We need systemic change. Still, it's a step in the right direction.

SaraICER announced an expansion of its scientific advice services, including earlier engagement and more comprehensive evidence reviews. This is a significant move for the US HTA landscape. It could help companies shape their evidence generation earlier.

MarcusThat's a positive development. Early engagement with HTA bodies is critical for efficient evidence generation. But I wonder if that's the full picture though. ICER's expansion comes as more payers are adopting similar models. The challenge will be ensuring consistency across different HTA frameworks.

SaraI'd frame it slightly differently: this is about access. If companies can get guidance earlier, they can avoid late-stage evidence gaps. That could reduce the risk of coverage denials. But the question is whether ICER can scale without compromising the depth of its reviews.

MarcusThe scalability issue is real. ICER has been stretched thin in the past. If they're expanding services, they'll need more resources. Also, how will this interact with the FDA's parallel processes? There's an opportunity for alignment, but also the risk of conflicting advice.

SaraThat's a critical point. The last thing companies need is mixed signals. The HEOR community will need to navigate both regulatory and HTA pathways simultaneously. The expansion of scientific advice could help, but only if it's coordinated.

MarcusExactly. And for us as practitioners, this means we need to be more strategic about when and how we engage with HTA bodies. The earlier, the better. But we must also be prepared for the complexity of multiple stakeholders.

SaraA lot to think about today. I'll be watching how the HCA situation unfolds and what it means for hospital-based access. The signals from the profit warning could reshape our evidence strategies.

MarcusSame — and for me the thread running through today is the increasing pressure on healthcare systems. From hospital finances to PBM practices to HTA expansion, the system is evolving rapidly. We need to be agile.

SaraThanks so much for listening — really glad you're here with us.

MarcusWe'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

Sara"Thanks for listening — see you tomorrow."

Marcus"Back tomorrow on Access Brief. Show notes at outcomes-analytica.no."